These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39226499)

  • 21. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
    Bhardwaja B; Klocke S; Ekinci E; Jackson A; Kono S; Olson KL
    BioDrugs; 2022 Jan; 36(1):1-11. PubMed ID: 34817847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
    Williamson R; Munro T; Ascher D; Robertson A; Pregelj L
    Value Health; 2024 Mar; 27(3):287-293. PubMed ID: 38141814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 25. Stakeholder perspectives on the sustainability of the United States biosimilars market.
    Sullivan SD; Humphreys SZ; Fox D; Lockhart CM; Tait-Dinger A; Betancourt JD; Komorny KM; Haumschild R; Chester B; Harman M; Roth JA
    J Manag Care Spec Pharm; 2024 Oct; 30(10):1065-1072. PubMed ID: 39012302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Market diffusion of biosimilars in off-patent biologic drug markets across Europe.
    Böhm AK; Steiner IM; Stargardt T
    Health Policy; 2023 Jun; 132():104818. PubMed ID: 37086662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Show Us (the U.S.) the Savings.
    Reinke T
    Manag Care; 2019 Jan; 28(1):9-10. PubMed ID: 30883315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.
    Stajszczyk M; Batko K; Żuber ZM; Kwiatkowska B; Krajewska-Włodarczyk M; Batko B
    BioDrugs; 2024 Jul; 38(4):557-569. PubMed ID: 38861154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Le Pen C; Sinègre M
    Appl Health Econ Health Policy; 2014 Jun; 12(3):315-26. PubMed ID: 24578185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.
    Jarrion Q; Azzouz B; Robinson J; Jolly D; Vallet C; Trenque T
    Therapie; 2022; 77(4):467-475. PubMed ID: 35027238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.
    San-Juan-Rodriguez A; Gellad WF; Good CB; Hernandez I
    JAMA Netw Open; 2019 Dec; 2(12):e1917379. PubMed ID: 31834391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Projected US savings from biosimilars, 2021-2025.
    Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
    Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of biological markets with multiple biosimilar competitors in the United States.
    Mouslim MC; Socal MP; Trujillo AJ
    Expert Opin Biol Ther; 2024 Nov; 24(11):1271-1278. PubMed ID: 39378044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
    Van de Wiele VL; Kesselheim AS; Sarpatwari A
    Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim.
    Grewal S; Ramsey S; Balu S; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):447-454. PubMed ID: 29757040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world evidence of a successful biosimilar adoption program.
    Humphreys SZ
    Future Oncol; 2022 May; 18(16):1997-2006. PubMed ID: 35296160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.